| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10916105 | Nuclear Medicine and Biology | 2011 | 7 Pages |
Abstract
Our results indicate that, despite its rapid metabolism, [18F]FBA-FALGEA-NH2 binds preferentially to EGFRvIII in the tumours in vivo and is a promising lead for further development of EGFRvIII specific peptide radiopharmaceuticals.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
![Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer](/preview/png/10916105.png "First Page Preview: Evaluation of 4-[18F]fluorobenzoyl-FALGEA-NH2 as a positron emission tomography tracer for epidermal growth factor receptor mutation variant III imaging in cancer")
Authors
Charlotte Lund Denholt, Tina Binderup, Marie-Thérése Stockhausen, Hans Skovgaard Poulsen, Mogens Spang-Thomsen, Paul Robert Hansen, Nic Gillings, Andreas Kjær,